CHICAGO (MedPage Today) -- The investigational protease inhibitor telaprevir, added to standard hepatitis C (HCV) treatment, produced a sustained virologic response in about half of patients who had previously failed with conventional therapy, a phase IIb trial showed.
hcv treatmentDDW: Telaprevir Improves HCV Clearance in Resistant Patients (CM...MedPage Today Infectious Disease Wed, 06/03/2009 - 10:19
Successful HCV Treatment May Not Eliminate Risk of TransmissionMedPage Today Infectious Disease Tue, 05/05/2009 - 13:21
TORONTO (MedPage Today) -- Even after successful treatment for hepatitis C, patients may have low levels of virus that could be infectious, Canadian researchers said. |
